William Blair Reinstates Outperform on CRISPR Therapeutics, Announces $75 Price Target
Portfolio Pulse from richadhand@benzinga.com
William Blair analyst Sami Corwin reinstates CRISPR Therapeutics (NASDAQ:CRSP) with an Outperform rating and announces a $75 price target.
May 30, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CRISPR Therapeutics receives an Outperform rating and a $75 price target from William Blair analyst Sami Corwin.
The reinstatement of an Outperform rating and a $75 price target by William Blair analyst Sami Corwin is a positive signal for CRISPR Therapeutics. This news is likely to boost investor confidence in the stock, potentially leading to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100